---
title: "Leerink Partners Keeps Their Hold Rating on Pfizer (PFE)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305778412.md"
description: "Leerink Partners analyst maintained a Hold rating on Pfizer yesterday. The company’s shares closed yesterday at $28.86.In addition to Leerink Partners, Pfizer also received a Hold from DZ BANK AG’s Elmar Kraus in a report issued on November 5. However, yesterday, Barclays maintained a Sell rating on Pfizer (NYSE: PFE)."
datetime: "2026-11-17T06:55:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305778412.md)
  - [en](https://longbridge.com/en/news/305778412.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305778412.md)
generator: "portal-rs"
---

# Leerink Partners Keeps Their Hold Rating on Pfizer (PFE)

Leerink Partners analyst maintained a Hold rating on Pfizer yesterday. The company’s shares closed yesterday at $28.86.

In addition to Leerink Partners, Pfizer also received a Hold from DZ BANK AG’s Elmar Kraus in a report issued on November 5. However, yesterday, Barclays maintained a Sell rating on Pfizer (NYSE: PFE).

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

- [Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments](https://longbridge.com/en/news/305966590.md)
- [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md)
- [Datapharm expands SRD Search into France](https://longbridge.com/en/news/305684420.md)
- [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md)
- [Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes](https://longbridge.com/en/news/305535476.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**